Royal London Asset Management Ltd. Has $66.24 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Royal London Asset Management Ltd. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 281,509 shares of the biopharmaceutical company's stock after acquiring an additional 1,759 shares during the quarter. Royal London Asset Management Ltd. owned 0.22% of Alnylam Pharmaceuticals worth $66,242,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Huntington National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the period. Larson Financial Group LLC increased its stake in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares during the period. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $33,000. OFI Invest Asset Management acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $35,000. Finally, True Wealth Design LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 153 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Remove Ads

Alnylam Pharmaceuticals Stock Up 2.6 %

ALNY traded up $7.36 during trading on Monday, reaching $290.70. 1,767,978 shares of the stock traded hands, compared to its average volume of 806,053. The stock's 50-day simple moving average is $257.16 and its two-hundred day simple moving average is $259.74. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market cap of $37.63 billion, a price-to-earnings ratio of -133.96 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ALNY. Bank of America upped their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday. Needham & Company LLC reissued a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday. Finally, Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $312.30.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company's stock, valued at $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last 90 days. 1.50% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.